Last reviewed · How we verify

Tobramycin + Dexamethasone

Umm Al-Qura University · FDA-approved active Small molecule Under review

Tobramycin + Dexamethasone is a Antibiotic + corticosteroid combination Small molecule drug developed by Umm Al-Qura University. It is currently FDA-approved for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis. Also known as: Tobradex.

Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response.

Tobramycin + Dexamethasone is a small molecule medication. It is used to treat various eye conditions, including cataract, as indicated by ClinicalTrials.gov.

At a glance

Generic nameTobramycin + Dexamethasone
Also known asTobradex
SponsorUmm Al-Qura University
Drug classAntibiotic + corticosteroid combination
TargetBacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaOphthalmology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and prevents protein synthesis, leading to bacterial cell death. Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses by inhibiting cytokine production and immune cell activation. Together, this combination addresses both the infectious and inflammatory components of ocular infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tobramycin + Dexamethasone

What is Tobramycin + Dexamethasone?

Tobramycin + Dexamethasone is a Antibiotic + corticosteroid combination drug developed by Umm Al-Qura University, indicated for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis.

How does Tobramycin + Dexamethasone work?

Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response.

What is Tobramycin + Dexamethasone used for?

Tobramycin + Dexamethasone is indicated for Bacterial ocular infections with inflammation, Post-operative ocular inflammation and infection prophylaxis.

Who makes Tobramycin + Dexamethasone?

Tobramycin + Dexamethasone is developed and marketed by Umm Al-Qura University (see full Umm Al-Qura University pipeline at /company/umm-al-qura-university).

Is Tobramycin + Dexamethasone also known as anything else?

Tobramycin + Dexamethasone is also known as Tobradex.

What drug class is Tobramycin + Dexamethasone in?

Tobramycin + Dexamethasone belongs to the Antibiotic + corticosteroid combination class. See all Antibiotic + corticosteroid combination drugs at /class/antibiotic-corticosteroid-combination.

What development phase is Tobramycin + Dexamethasone in?

Tobramycin + Dexamethasone is FDA-approved (marketed).

What are the side effects of Tobramycin + Dexamethasone?

Common side effects of Tobramycin + Dexamethasone include Ocular irritation or discomfort, Transient blurred vision, Allergic conjunctivitis, Increased intraocular pressure (with prolonged use).

What does Tobramycin + Dexamethasone target?

Tobramycin + Dexamethasone targets Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone) and is a Antibiotic + corticosteroid combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing